Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The purpose of this study is to find the best dose of ABBV-383 to treat AL amyloidosis. The people in this study have AL amyloidosis that came back or does not get better with treatment.
Researchers want to find the best dose of BBO-10203 to use in people with advanced solid tumors. The people in this study have one of these types of cancer that has spread (metastasized):
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to find the best dose of RMC-9805 to use in people with advanced solid tumors. The people in this study have cancer that keeps growing even with treatment. The tumors also have a mutation (change) in the KRAS gene called G12D.
Researchers want to find the best dose of TTI-101 that can be used safely alone and with other drugs for cancer. The people in this study have hepatocellular carcinoma (liver cancer) that has metastasized (spread) or is inoperable (surgically unremovable).
Researchers are assessing ado-trastuzumab emtansine (T-DM1) to treat salivary gland cancer. The people in this study have cancer that is operable (can be removed with surgery) and makes a protein called HER2. T-DM1 targets cancer cells that make HER2. In this study, it will be combined with radiation therapy and chemotherapy after the tumor has been removed by surgery.
Trastuzumab is an anticancer medication that targets HER2, a protein overproduced by some cancers of the stomach (gastric cancers) and the junction between the stomach and esophagus (gastro-esophageal junction or GEJ cancers). In this study, researchers are evaluating the safety of combining the drug trastuzumab deruxtecan (T-DXd) with immunotherapy and/or chemotherapy in patients with inoperable or metastatic stomach and GEJ cancers that have come back or continued to grow despite prior treatment.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to find the best dose of abemaciclib to combine with radiation therapy to treat advanced breast cancer. The people in this study have metastatic breast cancer that is fueled by estrogen or progesterone (hormone receptor-positive cancer). In addition, their breast cancer does not make a protein called HER2.
